Our Pricing

Switch to Wegovy: Private Prescription Without NHS Wait

Published on: June 03, 2026

Ready to switch to Wegovy private prescription UK without the months-long NHS waiting list? At Cured Pharmacy, you can access genuine UK-licensed Wegovy from £79.00 with a free online consultation completed in under 3 minutes, assessed by our UK-registered clinical team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

Why Patients Are Switching to Private Wegovy Prescriptions

NHS waiting lists for weight management services have extended significantly, with some patients facing 12-18 month delays before accessing specialist appointments. Meanwhile, private prescriptions offer immediate clinical assessment and next-day delivery, allowing you to begin treatment within 48 hours of your online consultation.

Wegovy (semaglutide 2.4mg) is the same medication dispensed through NHS weight management programmes, manufactured to identical MHRA standards [1]. The only difference is access speed and cost structure — private prescriptions eliminate waiting times but require out-of-pocket payment, while NHS prescriptions are free at point of delivery but subject to strict eligibility criteria and capacity constraints.

At Cured Pharmacy, we've supported thousands of UK patients through their weight management journey, providing the same clinical rigour as traditional GP services but with transparent upfront pricing and same-week treatment initiation. Every prescription is reviewed by a UK-registered prescriber following GMC and GPhC guidelines.

How Wegovy Works: The Science Behind Semaglutide

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural gut hormone called glucagon-like peptide-1. This hormone regulates appetite signals in the brain, slows gastric emptying, and improves insulin sensitivity — three mechanisms that work together to support sustainable weight reduction [1].

In the landmark STEP 1 trial published in the New England Journal of Medicine, participants using semaglutide 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [2]. Importantly, 86.4% of patients on semaglutide lost at least 5% of their baseline weight — the threshold associated with meaningful metabolic improvements including reduced blood pressure, improved lipid profiles, and lower HbA1c in patients with prediabetes.

Wegovy is administered as a once-weekly subcutaneous injection using a pre-filled pen device. Treatment follows a dose-escalation schedule starting at 0.25mg weekly, gradually increasing over 16-20 weeks to the maintenance dose of 2.4mg. This titration approach minimises gastrointestinal side effects, which are the most commonly reported adverse events during initiation [1][2].

Expected Timeline and Realistic Outcomes

Most patients begin noticing appetite reduction within the first 2-4 weeks of treatment, though measurable weight loss typically becomes evident from week 8 onwards. Clinical trials demonstrate that maximum weight reduction occurs around month 16-18, with weight stabilisation thereafter as long as treatment continues [2].

It's essential to understand that semaglutide is not a standalone solution — clinical trial participants received concurrent lifestyle intervention including dietary counselling and increased physical activity. Your UK prescriber will discuss realistic expectations during your consultation, and we recommend combining Wegovy with sustainable nutrition and movement habits for optimal long-term outcomes.

Wegovy Private Prescription Cost UK: Transparent Pricing Breakdown

At Cured Pharmacy, Wegovy is available from £79.00 per pen, with your exact monthly cost determined by your prescribed dose. Unlike some providers who advertise low prices but add hidden consultation fees or delivery charges, our pricing is completely transparent — the price you see during your free online assessment is the final price you pay.

Your treatment journey begins with a dose-escalation phase (typically 16-20 weeks) using lower-strength pens, before reaching the 2.4mg maintenance dose. During titration, monthly costs are lower as you use smaller doses. Once established on maintenance therapy, most patients require one 2.4mg pen every four weeks.

Every Wegovy prescription at Cured Pharmacy includes free online consultation with a UK-registered prescriber, discreet packaging with no pharmacy branding, and tracked delivery. There are no membership fees, no recurring charges without your explicit consent, and no pressure to commit beyond your initial prescription. You can pause, adjust, or discontinue treatment at any time in consultation with your prescriber.

Eligibility Criteria: Who Can Access Private Wegovy Prescriptions?

Wegovy is licensed by the MHRA for adults with a body mass index (BMI) of 30 kg/m² or above, or BMI 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [3]. These are the same clinical criteria used by NHS weight management services.

During your online consultation, our UK prescribers will calculate your BMI, review your medical history, assess any contraindications, and evaluate whether Wegovy is clinically appropriate for you. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, and pregnancy or breastfeeding [3].

Patients currently taking other GLP-1 receptor agonists (such as Ozempic for diabetes management) or those with a history of pancreatitis require careful clinical assessment before switching to or initiating Wegovy. Your prescriber will also review any medications you're currently taking to identify potential interactions, particularly with insulin or sulfonylureas which may require dose adjustment.

Switching from NHS to Private Prescription

If you're currently on an NHS waiting list or have been prescribed Wegovy through NHS services but are experiencing supply interruptions, switching to a private prescription is straightforward. You'll complete the same clinical assessment, and our prescribers can access your NHS summary care record (with your consent) to ensure continuity of care.

Many patients choose a hybrid approach — maintaining their NHS GP relationship for routine care while accessing weight management medications privately to avoid delays. This is entirely appropriate and ensures you receive timely treatment while remaining under your GP's overall supervision. We encourage you to inform your GP that you're using private prescription services, as this supports coordinated care.

How to Switch to Wegovy: The Cured Pharmacy Process

Our streamlined consultation process takes under 3 minutes to complete. You'll answer questions about your weight history, current medications, relevant medical conditions, and lifestyle factors. This information is reviewed by a UK-registered prescriber (doctor, nurse prescriber, or pharmacist prescriber) who will assess suitability and issue a prescription if clinically appropriate.

Once your prescription is approved — typically within 24 hours on weekdays — your Wegovy pen is dispensed from our GPhC-registered pharmacy (9012511) and dispatched via tracked courier. Most UK addresses receive delivery within 1-2 working days. All packaging is completely discreet with no external branding indicating pharmacy or medication contents.

After starting treatment, you'll receive follow-up emails at key intervals (week 4, week 12, week 24) inviting you to complete brief check-ins. These aren't mandatory but help our clinical team monitor your progress, address any side effects, and adjust dosing if needed. You can also contact our pharmacy team on (+44) 116 4646009 during business hours with any questions about administration technique, storage, or adverse effects.

Managing Side Effects and Maximising Treatment Success

The most frequently reported side effects with Wegovy are gastrointestinal: nausea (44% of trial participants), diarrhoea (30%), vomiting (24%), and constipation (24%) [2]. These symptoms are typically mild to moderate, occur predominantly during dose escalation, and diminish over time as your body adapts to the medication.

Practical strategies to minimise GI side effects include eating smaller, more frequent meals rather than large portions, avoiding high-fat foods which delay gastric emptying further, staying well-hydrated, and timing your injection for the same day each week when you can rest if needed. If nausea persists, your prescriber may slow the dose escalation schedule or prescribe anti-emetic medication as a temporary measure.

Rare but serious adverse effects include pancreatitis (characterised by severe persistent abdominal pain radiating to the back), gallbladder disease, and hypoglycaemia in patients taking concurrent diabetes medications [3]. You should seek immediate medical attention if you experience severe abdominal pain, persistent vomiting, visual changes, or signs of allergic reaction. Our clinical team provides detailed safety information with every prescription and remains available for advice throughout your treatment.

Long-Term Weight Maintenance After Wegovy

Clinical trial data shows that discontinuing semaglutide typically results in gradual weight regain, with the STEP 1 extension study demonstrating that participants regained approximately two-thirds of their lost weight within one year of stopping treatment [4]. This underscores that Wegovy is a long-term therapy rather than a short-term fix.

Successful long-term weight management requires integrating sustainable behaviour changes during your treatment period — establishing regular physical activity patterns, developing a balanced approach to nutrition, addressing emotional eating triggers, and building supportive social environments. Many patients find that the appetite reduction provided by Wegovy creates a valuable window to establish these habits, which then support weight maintenance even if medication is eventually tapered or discontinued.

Scientific References

1. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. NICE. [accessed 13 August 2026]
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and requires approval from a UK prescriber following online consultation. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment, lifestyle modification, and individual metabolic response.